NK cells as a possible new player in atopic dermatitis - 05/08/20
Doi : 10.1016/j.jaci.2020.04.052
Kenji Kabashima, MD, PhD a, b, ⁎ 
, Stephan Weidinger, MD c, ⁎
, Stephan Weidinger, MD c, ⁎ a Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
b Singapore Immunology Network (SIgN) and Skin Research Institute of Singapore (SRIS), Agency for Science, Technology and Research (A∗STAR), Biopolis, Singapore
c Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany
∗Corresponding author: Kenji Kabashima, MD, PhD, Department of Dermatology, Kyoto University Graduate School of Medicine, 54 Shogoin-Kawahara-cho, Sakyo, Kyoto 606-8507, Japan.Department of DermatologyKyoto University Graduate School of Medicine54 Shogoin-Kawahara-choSakyoKyoto606-8507Japan∗∗Stephan Weidinger, MD, Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Arnold-Heller-Str, 3 24105 Kiel, Germany.Department of Dermatology and AllergyUniversity Hospital Schleswig-HolsteinArnold-Heller-StrKiel3 24105Germany
Key words : NK cells, atopic dermatitis, CD56, IL-15, group 2 innate lymphoid cells, IL-4, IFN-γ
Il testo completo di questo articolo è disponibile in PDF.
| Disclosure of potential conflict of interest: K. Kabashima has received consulting fees or advisory board honoraria from Chugai Pharmaceutical, Japan Tobacco, Maruho, and Pola Pharma and research grants from AbbVie, Eli Lilly Japan, Japan Tobacco, Kyorin Pharmaceutical, Kyowa Hakko Kirin, LEO Pharma, Ono Pharmaceutical, P&G Japan, Pola Pharma, Sanofi, and Tanabe Mitsubishi. S. Weidinger is coprincipal investigator of the German Atopic Eczema Registry TREATgermany; has received institutional research grants from Sanofi Deutschland GmbH, Leo Pharma, and La Roche Posay; has performed consultancies for Sanofi-Genzyme, Regeneron, LEO Pharma, AbbVie, Pfizer, Eli Lilly, Kymab, and Novartis; has also lectured at educational events sponsored by Sanofi-Genzyme, Regeneron, LEO Pharma, AbbVie, Novartis, and Galderma; and is involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of psoriasis and atopic eczema. |
© 2020
Pubblicato da Elsevier Masson SAS.
Vol 146 - N° 2
P. 276-277 - Agosto 2020 Ritorno al numero
Articolo precedente
- Active control of mucosal tolerance and inflammation by human IgA and IgG antibodies
- Willianne Hoepel, Korneliusz Golebski, Cornelis M. van Drunen, Jeroen den Dunnen
- ILC2s: Are they what we think they are?
- Kellen J. Cavagnero, Taylor A. Doherty
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?